Pathstone Family Office’s MacroGenics MGNX Stock Holding History

Pathstone Family Office’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-160	Closed	-$1K	–	872
2020 Q1	$1K	Buy	+160	New	+$1.45K	﹤0.01%	721

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pathstone Family Office's MGNX Position: Q2 2020 in Review

Pathstone Family Office sold out of MacroGenics (MGNX) in Q2 2020, closing a stake of 160 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in MGNX in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 137 funds tracked by Wall St. Rank hold MGNX as of Q2 2020.

Pathstone Family Office reported no remaining MacroGenics position as of Q2 2020 after selling out during the quarter.
Pathstone Family Office sold 160 MacroGenics shares in Q2 2020, an estimated $1K.
Pathstone Family Office first reported a position in MacroGenics in Q1 2020 and held it in 1 quarter.
Pathstone Family Office's MacroGenics position peaked at $1K in Q1 2020.
137 funds tracked by Wall St. Rank held MacroGenics as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.